Schedule : Discussions by Track

Approaches and technologies to address early safety assessment

Failure rates in drug development due to adverse safety profiles are still a major problem in the industry. As a result, the pharmaceutical industry is increasingly focused on the characterisation of the safety profile in early discovery to de-risk and optimise compounds prior to further development. This session will look at approaches used to assess target organ toxicity in a discovery setting focusing on areas such as drug induced livery injury (DILI), cardiac safety assessment and immunosafety profiling of large molecules. Technology advances in this field, such as in iPSC derived and organ-on-a-chip models, will be discussed.

Conference close and Networking

Conference Introduction

The Auditorium
26-September-2019, at 09:00
Chairs: David Cronk, Ned Wakeman

Imaging techniques in Drug Discovery

This session will focus on the application of imaging techniques in drug discovery, including in vitro 3D imaging approaches, MS imaging and in vivo imaging applications. The use of imaging in drug discovery is becoming increasingly routine to inform decisions with applications ranging from high throughput screening to clinical assessment. This session will explore the use of imaging in fields including investigating disease specific pathophysiology’s, characterising the pharmacokinetics / pharmacodynamics of molecules and defining disease specific therapeutic endpoints

Mechanistic Enzymology in Drug Discovery

Enzymes constitute a significant proportion of the druggable genome and remain a rich source of drug targets. Initiating a successful strategy for developing a modulator of enzyme activity requires an understanding of the enzyme’s mechanism to understand how physiological conditions in disease relevant cells affect inhibitor potency. This understanding is critical to determine which mechanisms of inhibition and kinetic profiles translate into improved efficacy for a specific target. Recent developments, such as kinetic characterisation approaches, data analysis software and earlier assessment of mechanism are revitalising the focus on mechanistic enzymology in drug discovery. This session will explore the current state of the art in enzyme and inhibitor characterisation and the application to successful drug discovery.

Plenary Keynote

Poster Spotlight Presentations - Approaches and technologies to address early safety assessment

Poster Spotlight Presentations - Imaging techniques in Drug Discovery

Poster Spotlight Presentations - Mechanistic Enzymology in Drug Discovery

Session Chair Introductions

The Auditorium
26-September-2019, at 10:00
Chairs: Paul Walker, David Cronk
26-September-2019, at 10:00
Chairs: Clive Dilworth, Malcolm Haddrick
26-September-2019, at 10:00
Chairs: Geoff Holdgate, Dr Claire McWhirter

Technology Spotlight Presentations

Discovery Technologies 2019: Emerging Trends in Imaging, Safety Assessment and Enzymology

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Web Site Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
iPhone App
Android App
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2018